ALPMF (Astellas Pharma) YoY EPS Growth: 85.98% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALPMF Astellas Pharma Inc ALPMF
81 GF Score
Price $14.81
GF Value $15.35
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Astellas Pharma YoY EPS Growth?

Astellas Pharma ALPMF 81 YoY EPS Growth is 85.98% as of Jun. 2026. GuruFocus rates ALPMF with a GF Score™ of 81/100 and a GF Value™ of $15.35 (Fairly Valued). The stock has 5 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Astellas Pharma's YoY EPS Growth for the quarter that ended in Jun. 2026 was 85.98%.

Astellas Pharma's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $0.49.

Astellas Pharma YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma YoY EPS Growth Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.36 -28.32 -84.44 200.00 440.74

Astellas Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.50 112.86 201.13 -45.36 85.98
ALPMF
81GF Score
Astellas Pharma Inc ALPMF
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Astellas Pharma's YoY EPS Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EPS Growth (A: Mar. 2026 )
=(Earnings per Share (Diluted) (A: Mar. 2026 )-Earnings per Share (Diluted) (A: Mar. 2025 ))/ | Earnings per Share (Diluted) (A: Mar. 2025 ) |
=(1.022-0.189)/ | 0.189 |
=440.74 %

Astellas Pharma's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(0.491-0.264)/ | 0.264 |
=85.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 85.98% mean?
Astellas Pharma (ALPMF) has a YoY EPS Growth of 85.98% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Astellas Pharma and its competitors.
Is Astellas Pharma's YoY EPS Growth too high?
Astellas Pharma's current YoY EPS Growth is 85.98%. Overall, Astellas Pharma has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's YoY EPS Growth compare to LLY and JNJ?
Astellas Pharma's YoY EPS Growth of 85.98% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Astellas Pharma and its competitors. Astellas Pharma's current YoY EPS Growth is 85.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $15.35, compared to a current price of $14.81 — trading 3.5% below its estimated fair value. The current YoY EPS Growth is 85.98%. Astellas Pharma's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current YoY EPS Growth is 85.98% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $14.81 is trading 3.5% below its estimated GF Value™ of $15.35. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • YoY EPS Growth: 85.98%
  • GF Value™: $15.35 vs. price of $14.81 (3.5% below fair value)
  • GF Score™: 81/100 with 5 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
81GF Score

Get the complete analysis for ALPMF

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.81
Price
$15.35
GF Value